

CURRICULUM VITAE

David R. Taft, Ph.D.

CONTACT INFORMATION: Division of Pharmaceutical Sciences
Long Island University
Brooklyn, NY 11201
TEL: 718-488-1632
FAX: 718-780-4586
EMAIL: dtaft@liu.edu

EDUCATION

University of Rhode Island, College of Pharmacy, Kingston, RI 02881.
Bachelor of Science, Pharmacy, With Highest Distinction, May 1987.

University of Connecticut, School of Pharmacy, Storrs, CT 06269.
Doctor of Philosophy, Pharmaceutical Science, May 1993.
Advisor: Kevin R. Sweeney, Ph.D.

University of North Carolina, School of Pharmacy, Chapel Hill, NC 27599.
Postdoctoral Fellow, Pharmacokinetics, 1993-1994.
Advisors: Gary M. Pollack, Ph.D.
Kim L.R. Brouwer Pharm.D., Ph.D.

ACADEMIC EXPERIENCE

January 2008 to present, Director, Division of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY 11201
September, 2005 to present. Associate Professor with Tenure, Division of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY 11201.
September, 2000 to August 2005. Associate Professor with Tenure, Division of Pharmaceutics and Industrial Pharmacy, Arnold & Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY 11201.
June, 1994 to September, 2000. Assistant Professor, Division of Pharmaceutics and Industrial Pharmacy, Arnold & Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY 11201.

HONORS AND AWARDS

American Association of Colleges of Pharmacy Academic Leadership Fellow, 2004-2005
Founders Award for Faculty, Arnold & Marie Schwartz College of Pharmacy, Long Island University, 2002
American Association of Pharmaceutical Scientists New Investigator Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism, 1998
David Newton Award for Excellence in Teaching, Long Island University, 1997
American Foundation for Pharmaceutical Education (AFPE) Fellow, 1989-1992

PROFESSIONAL ASSOCIATIONS

American Association of Pharmaceutical Scientists
American Association of Colleges of Pharmacy
Phi Lambda Sigma Pharmacy Leadership Society
Rho Chi Pharmacy Honor Society

EDITORIAL BOARD APPOINTMENTS

Journal of Pharmaceutical Sciences (2003 – present)
Drug Development and Industrial Pharmacy (2005- present)
Current Drug Discovery Technologies (2007-present)
Current Medical Research and Opinion (International Advisory Board, 2007-present)

GRANTS/CONTRACTS

Genzyme Oncology Inc, “Pharmacokinetic Studies with Clofarabine and Other Nucleoside Analogs: In Vivo and Isolated Perfused Kidney Studies”, \$70,000, 2007
Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, \$68,550, 2007
Genzyme Oncology Inc, “Renal Excretion of Clofarabine in the Isolated Perfused Rat Kidney: Assessment of Dose Linearity and Role of Renal Transport Systems on Drug Excretion”, \$44,000, 2007
Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, \$68,894, 2006
Vertex Pharmaceuticals Inc, “Renal Excretion of a Novel Compound in the Isolated Perfused Rat Kidney: Assessing Potential Interaction with Methotrexate”, \$18,000, 2006
Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, \$60,000, 2005
Shire Pharmaceutical Development, “Assessment of Dose Linearity of the Renal Clearance of SPD-754 and its Metabolite BCH335 in the Isolated Perfused Rat Kidney”, \$29,975, 2004.

- Shire Pharmaceutical Development, "Effect of Potential Interactants on the Renal Disposition of SPD-754 and BCH-355 in the Isolated Perfused Rat Kidney", \$24,706, 2004.
- Shire Pharmaceutical Development, "Effect of Trimethoprim on the Renal Disposition of BCH-335 in the Isolated Perfused Rat Kidney", \$21,670, 2003.
- Shire Pharmaceutical Development, "Effect of Trimethoprim on the Renal Disposition of SPD-754 and 3TC in the Isolated Perfused Rat Kidney", \$42,600, 2003.
- 1996-1997 New Investigators Program Grant, American Association of Colleges of Pharmacy, "Investigation of a Facilitative Role of Albumin in Renal Clearance", \$10,000.

PUBLICATIONS

1. Tomoko Nakatani-Freshwater and David R. Taft. Renal Excretion of Emtricitabine II. Effect of Trimethoprim on Emtricitabine Excretion: In Vitro and In Vivo Studies. *Journal of Pharmaceutical Sciences* (In Press).
2. Tomoko Nakatani-Freshwater and David R. Taft. Renal Excretion of Emtricitabine I. Effects of Organic Anion, Organic Cation, and Nucleoside Transport Inhibitors on Emtricitabine Excretion. *Journal of Pharmaceutical Sciences* (In Press).
3. David R. Taft, Ishani A. Savant, Aruna Dontabhaktuni, Mariana Babayeva and Tomoko Nakatani-Freshwater. Application of the Isolated Perfused Rat Kidney Model to Assess Gender Effects on Drug Excretion. *Drug Development and Industrial Pharmacy* 32(8):919-28, 2006.
4. Tomoko Nakatani-Freshwater, Mariana Babayeva,, Aruna Dontabhaktuni, and David R. Taft. Effects Of Trimethoprim On The Clearance Of Apricitabine, A Deoxycytidine Analog Reverse Transcriptase Inhibitor, And Lamivudine In The Isolated Perfused Rat Kidney. *Journal of Pharmacology and Experimental Therapeutics* 319(2):941-947, 2006.
5. Madiha B. Sidhom, Nadya Rivera, Hassan Almoazen, Harold L. Kirschenbaum, and David R. Taft. Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations. *International Journal of Pharmaceutical Compounding* 9(5):402-406, 2005.
6. Roda Plakogiannis, Henry Cohen, and David Taft. Effects Of Morning Versus Evening Administration Of Atorvastatin In Patients With Hyperlipidemia. *American Journal of Health Systems Pharmacy* 62(23):2491-2494, 2005.
7. Mohammed A. Kabir, David R. Taft, Cecil K. Joseph, and Robert A Bellantone. Measuring Drug Concentrations Using Pulsatile Microdialysis: Theory and Method Development In Vitro. *International Journal of Pharmaceutics*, 293:171-182, 2005.
8. David R. Taft. The Isolated Perfused Rat Kidney Model: A Useful Tool for Drug Discovery and Development. *Current Drug Discovery Technologies*,1:97-111, 2004.
9. Nagaraju R. Poola, Michelle Kalis, Fotios Plakogiannis and David R. Taft. Characterization of Pentamidine Excretion in the isolated Perfused Rat Kidney. *Journal of Antimicrobial Chemotherapy* 52(3):397-404, 2003.
10. Mohammed Nasser Ali Christy, Robert A. Bellantone, David R. Taft and Fotios .M. Plakogiannis. In Vitro Evaluation Of The Release Of Albuterol Sulfate From Polymer

- Gels: Effect Of Fatty Acids On Drug Transport Across Biological Membranes. *Drug Development and Industrial Pharmacy* 28:1221-1229, 2002..
11. Malaz AbuTarif, Ganesh R. Iyer, Vidya Sankaragarayanan, Robert A. Bellantone and David R. Taft. Erythrocyte Distribution Kinetics of the Carbonic Anhydrase Inhibitor Methazolamide: Application of *In Vitro* Studies to Predict *In Vivo* Drug Disposition. In: SG Pandalai (Ed) *Recent Developments in Drug Metabolism Vol 1*, pp:117-131, 2002.
 12. Nagaraju R. Poola, Dider Bhuiyan, Michelle Kalis, Stephan Ortiz, Ishani A. Savant, Harold Kirschenbaum, Madiha Sidhom and David R. Taft. A Novel HPLC Assay for Pentamidine: Comparative Effects of Creatinine and Inulin on GFR Estimation and Pentamidine Renal Excretion in the Isolated Perfused Rat Kidney. *Journal of Pharmacy and Pharmaceutical Sciences* 5(2):130-140, 2002.
 13. Malaz A. AbuTarif and David R. Taft. Simulation of the Pharmacokinetic Profile of Methazolamide in Blood: Effect of Carbonic Anhydrase Binding on Drug Disposition. *Pharmaceutical Research* 19:551-555, 2002.
 14. Ishani A. Savant, Michelle Kalis, Hassan Almoazen, Stephan R. Ortiz, Malaz AbuTarif and David R. Taft. Alternative High-Performance Liquid Chromatographic Assay for p-Aminohippuric Acid (PAH): Effect of Aging on PAH Excretion in the Isolated Perfused Rat Kidney. *Journal of Pharmaceutical and Biomedical Analysis* 26:687-699, 2001.
 15. Ganesh R. Iyer, Robert A. Bellantone and David R. Taft. *In Vitro* Characterization of the Erythrocyte Distribution of Methazolamide: A Model of Erythrocyte Transport and Binding Kinetics. *Journal of Pharmacokinetics and Biopharmaceutics* 27,45-66, 1999.
 16. David R. Taft, Sean Nordt, Ganesh R. Iyer, and Michael H. Schwenk. Blood Disposition and Urinary Excretion Kinetics of Methazolamide Following Oral Administration to Human Subjects. *Biopharmaceutics and Drug Disposition* 19(6):373-380, 1998.
 17. David R. Taft. One-Compartment Model with Zero-Order Input: The Constant Rate Intravenous Infusion. *American Journal of Pharmaceutical Education* 62(2):170-176, 1998.
 18. Ganesh R. Iyer and David R. Taft. Determination of Methazolamide Concentrations in Human Biological Fluids by High Performance Liquid Chromatography. *Journal of Pharmaceutical and Biomedical Analysis* 16(6):1019-1024, 1998.
 19. David R. Taft, Ganesh R. Iyer, Leon Behar and Robert V. DiGregorio. Application of a First-Pass Effect Model to Characterize the Pharmacokinetic Disposition of Venlafaxine Following Oral Administration to Human Subjects. *Drug Metabolism and Disposition* 25:1215-1218, 1997.
 20. Christopher J. Matheny, David R. Taft, Kim L.R. Brouwer and Gary M. Pollack. Evidence for Reversible Sequestration of Morphine in Rat Liver. *Biochemical Pharmacology* 52:535-541, 1996.
 21. David R. Taft, Donna J. Fournier, Dennis J. Chapron and Kevin R. Sweeney. Concentration Dependent Tubular Secretion of Acetazolamide and its Inhibition by Salicylic Acid in the Isolated Perfused Rat Kidney. *Drug Metabolism and Disposition* 24(4):456-451, 1996.
 22. Kevin R. Sweeney, Poe-Hirr Hsyu, Paul Statkevich, and David R. Taft. Renal Disposition and Drug Interaction Screening of (-)-2'-Deoxy-3'-Thiacytidine (3TC) in the Isolated Perfused Rat Kidney. *Pharmaceutical Research* 12(12):1958-1963, 1995.

23. David R. Taft and Kevin R. Sweeney. The Influence of Protein Binding on the Elimination of Acetazolamide by the Isolated Perfused Rat Kidney: Evidence of Albumin-Mediated Tubular Secretion. *Journal of Pharmacology and Experimental Therapeutics* 274:752-760, 1995.

EDITED WORKS

- Robert O. Williams III, David R. Taft and Jason T. McConville (Eds), *Advanced Drug Formulation Design to Optimize Therapeutic Outcomes*, New York, Informa Healthcare, 2007.
- Mark C. Rogge and David R. Taft (Eds), *Preclinical Drug Development*, New York, Informa Healthcare, 2005.

RESEARCH ABSTRACTS (2000-PRESENT)

1. M. Babayeva, S. Cox, and D.R. Taft. Renal Excretion of Apricitabine: Ex Vivo Assessment of Potential Drug:Drug Interactions. *The AAPS Journal* 9(S2), Abstract W4509, 2007.
2. A. Ajavon, P.L. Bonate, and D.R. Taft. Renal Excretion of Clofarabine in the Isolated Perfused Rat Kidney: Assessment of Dose Linearity and Role of Renal Transport Systems on Drug Excretion. *The AAPS Journal* 9(S2), Abstract W4439, 2007.
3. A. Dontabhaktuni, D.R. Taft and W. Zarycranski. Effect of Urinary Alkalinization and Cimetidine Co-Administration on Gentamicin Excretion in The Isolated Perfused Rat Kidney: Strategies to Limit Kidney Accumulation Of A Nephrotoxic Compound. *The AAPS Journal* 8(S2), Abstract T3327, 2006.
4. T. Nakatani-Freshwater, D.R. Taft, and B. Kearney. Renal Excretion of Emtricitabine In the Isolated Perfused Rat Kidney. *The AAPS Journal* 8(S2), Abstract W5306, 2006.
5. T. Nakatani-Freshwater, D.R. Taft, and B. Kearney. Effect of Trimethoprim on the Renal Disposition of Emtricitabine in the Isolated Perfused Rat Kidney. *The AAPS Journal* 8(S2), Abstract T3333, 2006.
6. R.E. Freshwater, M. Maniar and D.R. Taft. Cross-Species Pharmacokinetic Comparison of a Novel Anticancer Agent, ON.01910.Na. *The AAPS Journal* 8(S2), Abstract W4355, 2006.
7. R.E. Freshwater, M. Maniar and D.R. Taft. Preclinical Pharmacokinetics of Ex-RAD™, a Novel Radioprotective Agent. *The AAPS Journal* 8(S2), Abstract W4356, 2006.
8. R.E. Freshwater, M. Maniar, and D.R. Taft. Effect Of Route Of Administration and Formulation on the Plasma Exposure Of Ex-RAD™ in Rats. *The AAPS Journal* 8(S2), Abstract W4178, 2006.
9. T. Nakatani-Freshwater, M. Slugocki, S. Sivakumar, E. Freshwater, M. Babayeva, and D.R. Taft. Effect of Tenofovir on the Renal Excretion of Didanosine in the Isolated Perfused Rat Kidney. *The AAPS Journal* 7(S2), Abstract T3313, 2005
10. A Dontabhaktuni and D.R. Taft. Renal Excretion of Gentamicin in the Isolated Perfused Rat Kidney. *The AAPS Journal* 7(S2), Abstract T3268, 2005
11. A Dontabhaktuni, M. B. Sidhom and D.R. Taft. An Alternative HPLC Assay for Gentamicin. *The AAPS Journal* 7(S2), Abstract T3037, 2005

12. I.A. Savant, S.R. Ortiz and D.R. Taft. Gender Differences in Organic Anion Excretion in the Isolated Perfused Rat Kidney. *AAPS PharmSci* 5(4), Abstract R6181, 2003.
13. S.R. Ortiz, I.A. Savant, A. Dontabhaktuni, and D.R. Taft. Effects of Hypoalbuminemia and Protein Binding Displacement on Furosemide Excretion in the Isolated Perfused Rat Kidney. *AAPS PharmSci* 4(4), Abstract W5280, 2002.
14. N.R. Poola and D.R. Taft. A Mathematical Model of Pentamidine Excretion in the Isolated Perfused Rat Kidney. *AAPS PharmSci* 4(4), Abstract W5281, 2002.
15. M.A. Abutarif and D.R. Taft. Non-Instantaneous Complexation Kinetics Between Methazolamide and CA Enzymes I and II. *AAPS PharmSci* 4(4), Abstract W5250, 2002.
16. M.A. Abutarif and D.R. Taft. Plasma Protein Binding Determination of Genestein, a Major Ingredient in Soy. *AAPS PharmSci* 3(3), Abstract, 2001.
17. N.R. Poola, S.R. Ortiz, I.A. Savant, and D.R. Taft. Pentamidine Renal Excretion in the Isolated Perfused Rat Kidney. *AAPS PharmSci* 3(3), Abstract, 2001.
18. M.A. Abutarif, R.A. Bellantone, S.R. Ortiz, I.A. Savant, and D.R. Taft. Simulation of the Pharmacokinetic Profile of Methazolamide in Blood. Effect of Carbonic Anhydrase on Drug Disposition. *AAPS PharmSci* 3(3), Abstract, 2001.
19. N. Poola, S Ortiz, I. Savant, M. AbuTarif and D.R. Taft. Renal Disposition of Pentamidine in the Isolated Perfused Rat Kidney: Differential Effects of Creatinine and Inulin on Drug Excretion. *AAPS PharmSci*, Abstract 1112, 2000.